RECURSION PHARMACEUTICALS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $723.0K | $542.9M | $285.1M |
| FY2022 | — | $485.8M | $549.9M |
| FY2023 | — | $463.4M | $391.6M |
| FY2024 | — | $1.03B | $594.4M |
| FY2025 | — | $1.13B | $743.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $723.0K | $542.9M | $285.1M |
| FY2022 | — | $485.8M | $549.9M |
| FY2023 | — | $463.4M | $391.6M |
| FY2024 | — | $1.03B | $594.4M |
| FY2025 | — | $1.13B | $743.3M |